Every letter we have printed

Aspartate isomerisation changes nothing about the mass at all. Nor does racemisation of a single residue. Both alter the molecule in ways that a chromatographic method developed for the purpose can sometimes resolve, and that a mass measurement cannot see under any circumstances.

I disagree with rather more of this than I expected to and I am glad it was printed. An argument I can take issue with is more use than a summary I cannot.

Background incidence is the missing comparator in nearly every discussion of rare events. Some of the conditions named in this context occur at a measurable rate in an untreated population of similar age and composition, and the rate is rarely quoted alongside.

Case reports are hypothesis-generating and are cited as though they were confirmatory. A single well-documented case is genuinely valuable and it establishes that something can happen, not how often.

Worth adding that endotoxin survives conditions that kill the organism that made it. A process can eliminate every viable cell and leave the pyrogenic material entirely intact, which is why the two tests exist separately and why passing one says nothing about the other.

Community discussion is dominated by what can be verified cheaply, and verification cost determines which topics are live. This one has no cheap verification available to an individual, so it does not become a topic.

Coring is the failure mode that follows repeated withdrawals from one stopper, and it produces exactly the particulate your article warns about. The number of entries a closure is qualified for is a real specification and it is never stated on anything sold in this market.

Your endotoxin table gives vial 12 at 112 EU per vial and then declines to say whether that is dangerous. I understand why. It is still frustrating to read a figure of that size next to the sentence "arithmetic, not a safety assessment".

Depyrogenation of glassware is a defined process with defined conditions, and a vial that has been washed rather than depyrogenated is a different container. Nobody in this market states which was done.

A result on one vial from a lot is a result about that vial. Endotoxin contamination is frequently sporadic rather than uniform, which is precisely why pharmacopoeial sampling plans specify more than one unit.

Filtration through a sterilising-grade membrane is not sterilisation of the product unless everything downstream of the filter is controlled. The filter is one step in a system, and a filter certificate on its own supports a much narrower claim than the marketing usually built on it.

Interference is a real problem for peptide samples in these assays, and a laboratory that does not report an inhibition or enhancement check has not established that the result is valid for that matrix.

The people best placed to change this are the testing services rather than the suppliers. A service that offered the determination as a standard part of its panel would create the expectation in one season.

A note on scale. A supplier filling thousands of units has a fixed-cost argument for better process control that a small operation does not, and the market’s structure therefore affects what is even feasible. That is worth a piece in its own right.

Where the substudy population volunteered for an additional scan, they are a self-selected subset of an already selected trial population. Two layers of selection, and every figure downstream inherits both.

The comparison that would put these figures in proportion is composition change under any other route to the same mass loss. That comparison exists in the older literature, it is unflattering to the argument on both sides, and it is almost never cited.

Density and quality are different properties and only the first is measured. A change in density with unchanged architecture and a change in both have very different implications, and the common instrument cannot distinguish them.

The smallest change an instrument can resolve is the number readers most need and are least often given. Below that threshold a difference between two scans is not a small change; it is not a change at all, and treating it as one drives a great deal of unnecessary anxiety.

A word of appreciation for the practice of quoting the sample size beside every figure. It has quietly deflated a good deal of what I used to believe.

A short interruption and a long one are not the same event and are discussed as though they were. Missing one weekly dose leaves substantial exposure in place; missing six weeks does not. The threshold is a matter of arithmetic and nobody prints it.

The length of the interruption must matter and no threshold has been established anywhere. Advice that specifies a duration is specifying a number nobody has measured.

Receptor occupancy arguments are used loosely in this discussion. Occupancy and effect are related by a function that is rarely linear, and quoting a saturation figure as though it settled the question is not supported by the pharmacology.

The badges that do resolve to a third-party page are a genuine improvement and deserve saying so. I have followed several from companies in your dossier programme and reached a report with a number, a date and a lot on it, which is precisely what the mechanism is for.

I administer a small purchasing budget and I have stopped treating marks of this kind as evidence at all. Not because they are dishonest, but because I cannot tell from the mark which of the honest cases I am looking at, and a signal I cannot decode is not a signal.

Ambient during transport home from a delivery point is part of the in-use history and is never counted. A parcel collected on a warm afternoon and carried across town has had an excursion before anybody opened it.

Light exposure is trivially controllable and almost never controlled. A clear vial on a shelf near a window is running a photostability study nobody designed, and the effect is real for several residue types.

Labelling the date of reconstitution on the vial is the single practice that would improve this most, and it requires a marker pen. Half the uncertainty in these discussions is uncertainty about how long something has been sitting.

Bacteriostatic diluent contains a preservative and is intended for multiple withdrawals; sterile water is not. That distinction is the one thing in this whole subject that a supplier could usefully print on the box, and I have never seen it printed. Research-use material is not approved for human use in any event, and the storage physics is the same either way.

The most reported response in every account I have collected is to wait, and waiting is not described as a strategy in any formal source. The commonest behaviour in the field has no name in the literature.

A note about what people actually do, from somebody who reads a great deal of it. The most common response reported is to wait, and waiting is almost never described in the formal literature as a strategy even though it appears to be the dominant one.

Tachyphylaxis in the emptying effect is well described and rarely mentioned outside the specialist literature. A mechanism that attenuates over weeks explains a great deal of the time course that otherwise looks mysterious.

Severity grading is doing a lot of quiet work. Most reported events sit in the mild to moderate categories, and a table that reports incidence without severity puts an inconvenience and a serious event in the same column.

Printing the reasoning rather than only the conclusion is what makes this publication worth the subscription. Please keep doing it even when it makes the pieces longer.

Ion-exchange deserves a place beside size-exclusion in your list of second principles. Deamidation shifts charge without shifting mass or hydrophobicity appreciably, so it is close to invisible in reversed phase and obvious on a charge-based separation. For an ageing peptide it is the question worth asking.

Mass spectrometric detection on the same chromatographic run gives you an orthogonality of a sort for nothing, because a co-eluting species of different mass will show up in the extracted trace even when the ultraviolet peak looks clean. The separation is not orthogonal but the detection is, and for the co-elution question that is what matters.

Receptor pharmacology tells you what can happen and outcome studies tell you what does. Presenting the first as though it settled the second is the commonest error in coverage of this class, and it is committed by people who know better.

Long-term receptor pharmacology is genuinely unknown territory, and the honest statement is that the exposure durations now being contemplated exceed the durations that have been studied. That is not alarming and it is not nothing, and it should be said in both those registers at once.

A small thing: you write "class B GPCR" and then "secretin-like receptor" as though these were different classifications. They are the same family under two naming conventions, and the piece would be clearer if it said so.

I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.

Thank you for printing the letters that disagree with the desk at the same length as the ones that do not. It is a small editorial choice with a large effect on how the column reads.